Do Traders Think Revolution Medicines Inc (RVMD) Can Turn Around Monday?

Revolution Medicines Inc (RVMD) stock is lower by 9.84% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Revolution Medicines Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RVMD!

See Full RVMD Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With RVMD Stock Today?

Revolution Medicines Inc (RVMD) stock has fallen -1.5% while the S&P 500 has gained 0.02% as of 12:46 PM on Monday, Nov 13. RVMD has fallen -$0.29 from the previous closing price of $19.71 on volume of 489,029 shares. Over the past year the S&P 500 has risen 11.60% while RVMD has fallen -8.48%. RVMD lost -$3.26 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Revolution Medicines Inc click here.

More About Revolution Medicines Inc

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Click Here to get the full Stock Report for Revolution Medicines Inc stock.